hsa-miR200a-3p和hsa-miR502-3p作为阿尔茨海默病血液生物标志物的潜力。
Potential of hsa-miR200a-3p and hsa-miR502-3p as blood-based biomarker for Alzheimer's disease.
作者信息
Biglari Negin, Khalaj-Kondori Mohammad, Ghasemi Tayyebeh
机构信息
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
出版信息
Mol Biol Rep. 2022 Dec;49(12):11925-11932. doi: 10.1007/s11033-022-07987-w. Epub 2022 Oct 17.
BACKGROUND
Alzheimer's disease (AD) is one of the most important known dementia which affects thousands of people every year. Many factors are involved in this process, such as aberrant expression of miRNAs.
METHODS AND RESULTS
Firstly, we analyzed two microarray datasets related to AD (GSE48552, GSE129053) to identify the differentially expressed miRNAs, and two miRNAs were selected for further validation. Dataset analysis showed that the expression of hsa-miR200a-3p and hsa-miR502-3p were up-regulated in AD. These findings were validated in plasma samples by qRT-PCR. ROC curve analysis showed that plasma levels of both miRNAs might discriminate the AD and healthy controls. In addition, in silico analysis revealed that the upregulation of these miRNAs could promote AD progression via affecting the expression of target molecules mainly ATF6 and dynactin.
CONCLUSION
Totally, hsa-miR200a-3p and hsa-miR502-3p are upregulated in AD and their plasma levels can discriminate AD and healthy people, highlighting their potential as blood-based biomarker for AD.
背景
阿尔茨海默病（AD）是已知的最重要的痴呆症之一，每年影响着数千人。许多因素参与了这一过程，例如微小RNA（miRNA）的异常表达。
方法与结果
首先，我们分析了两个与AD相关的基因芯片数据集（GSE48552、GSE129053）以鉴定差异表达的miRNA，并选择了两个miRNA进行进一步验证。数据集分析表明，hsa-miR200a-3p和hsa-miR502-3p在AD中表达上调。这些发现通过qRT-PCR在血浆样本中得到验证。ROC曲线分析表明，两种miRNA的血浆水平可能区分AD患者和健康对照。此外，生物信息学分析显示，这些miRNA的上调可通过影响主要靶分子ATF6和动力蛋白激活蛋白的表达促进AD进展。
结论
总体而言，hsa-miR200a-3p和hsa-miR502-3p在AD中上调，其血浆水平可区分AD患者和健康人，突出了它们作为AD血液生物标志物的潜力。
Zotero 插件